Overview of prognostic factors in adult glioma; a 10-year experience at a single institution

3

4 Amir Barzegar Behrooz^{1,2,3}, Hadi Darzi Ramandi^{4,5}, Hamid Latifi-Navid^{2,6,7}, Payam

5 Peymani⁸, Rahil Tarharoudi^{3,9}, Nasrin Momeni^{3,9}, Mohammad Mehdi Sabaghpour Azarian¹⁰,

- 6 Sherif Eltonsy⁸, Ahmad Pour-Rashidi^{3,11*}, Saeid Ghavami^{1,12,13, 14*}
- 7
- ¹Department of Human Anatomy and Cell Science, University of Manitoba College of
 Medicine, Winnipeg, Manitoba, Canada
- 10 ²Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences,
- 11 Tehran, Iran
- ³Brain Cancer Research Group, Department of Cancer, Asu vanda Gene Industrial Research Company,
- 13 Tehran 1533666398, Iran
- ⁴Department of Biostatistics, Asu vanda Gene Industrial Research Company, Tehran1533666398, Iran
- ⁵Department of Biotechnology, Bu-Ali Sina University, Hamedan, Iran
- ⁶Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology,
- 17 14965/161, Tehran, Iran
- ⁷School of Biological Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran
- ⁸College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba
- ⁹Department of Molecular and Cellular Sciences, Faculty of Advanced Science and Technology,
- 21 Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
- ¹⁰Department of Biotechnology, Asu vanda Gene Industrial Research Company, Tehran 1533666398,
- 23 Iran
- ¹¹Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
- ²⁵ ¹²Academy of Silesia, Faculty of Medicine, Katowice, Poland.
- ¹³Biology of Breathing Theme, Children Hospital Research Institute of Manitoba, University of
 Manitoba, Winnipeg, Manitoba, Canada
- 28 ¹⁴Research Institute of Oncology and Hematology, Cancer Care Manitoba-University of Manitoba,
- 29 Winnipeg, Manitoba, Canada
- 30 * These authors have co-senior authorship.
- *Correspondence Dr. Ahmad Pour-Rashidi, Department of Neurosurgery, Sina Hospital, Tehran
 University of Medical Sciences, Tehran, Iran.
- 33
- 34
- 35
- 36
- 37

38 Abstract

Objective: The most prevalent central nervous system (CNS) neoplasm arising from glial cells is glioma, which diffusely invades brain tissue. Among gliomas, Glioblastoma (GBM) is a glioma of the highest grade and associated with a grim prognosis, with a median overall survival of 15 months with and 3-4 months without therapy. We examined how clinical variables and molecular profiles may have affected overall survival (OS) at Sina Hospital in Tehran over the past ten years.

45 Methods: A retrospective study was conducted at Sina Hospital in Tehran, Iran, and 46 examined patients ≥ 11 years with confirmed glioma diagnoses between 2012 and 2020. We 47 evaluated the correlation between OS in GBM patients and sociodemographic as well as 48 clinical factors, including age, gender, extent of tumor resection, tumor location, 49 chemo/radiotherapy, and molecular profiling based on IDH1, MGMT, TERT, and EGFR 50 status. Kaplan-Meier and multivariate Cox regression models were used to assess patient 51 survival.

52 **Results:** Following a comprehensive evaluation of medical records, 186 patients were 53 enrolled in the study. The median OS was 20 months, with a 2-year survival rate of 62.5%. 54 Among the 132 patients with available IDH measurements, 105 (79.5%) exhibited IDH1 55 wild-type tumors. Of the 132 patients with assessed MGMT methylation, 94 (71.2%) had 56 MGMT methylated tumors. TERT promoter methylation was detected in 112 out of 132 cases 57 (84.8%), while no methylation was observed in 20 cases (15.2%). Analyses using 58 multivariable models revealed that age at histological grade (P < 0.0001), adjuvant 59 radiotherapy (P < 0.014), IDH1 status (P < 0.026), and TERT promoter status (P < 0.030) 60 were independently associated with OS.

61 **Conclusion:** The findings of this study demonstrate that patients with higher tumor 62 histological grades who had received adjuvant radiotherapy, exhibited IDH1 mutations, or 63 presented with TERT promoter mutations, experienced improved OS. The median survival 64 time was 20 months, with 15.6% and 46.9% of patients surviving at 12 and 24 months, 65 respectively.

66 Keywords: Glioma; Glioblastoma; Overall survival; Genomic profiling; Tumor heterogeneity

67

68 Introduction

Gliomas are primary brain lesions involving cerebral structures without well-defined 69 70 boundaries and constitute the most prevalent central nervous system (CNS) neoplasms. Glioblastoma (GBM) is a glioma of the highest grade with, has a very dismal prognosis. 71 Gliomas can develop at any age, but are most common in older adults ^{1, 2}. Patients with GBM 72 under 70 years of age showed a median lifespan of around 14.6 months, even with the best 73 current standard of treatment, which includes adjuvant chemotherapy with temozolomide 74 75 (TMZ) and chemoradiotherapy after tumor excision. Population-based research indicates that chances of survival decline with age $^{3, 4}$. 76

77 Considering most GBM patients pass away from the illness in under a year and almost 78 none survive long-term, GBM tumors have attracted a lot of interest in the research community⁵. Even after extensive surgery, concomitant radiation, adjuvant TMZ, and 79 rigorous treatment, the median survival period for adult patients is still only around ten 80 months, which may get up to 14 months with combination treatment and radiation; just 3-5% 81 of patients live longer than three to five years after diagnosis ⁶⁻⁸. In addition to patient 82 characteristics like age and gender, biological variables such as O⁶-methylguanine-DNA 83 methyltransferase (MGMT) promoter methylation status, 1p/19q deletion, and \Box isocitrate 84 dehydrogenase 1 (IDH1) gene mutation status may impact disease susceptibility and 85 progression⁹, which makes predicting GBM survival a challenging task. 86

Age at diagnosis, surgical resection, tumor grade, chemo/radiotherapy, and genetic profiling affect glioma survival. This study evaluated the characteristics of glioma patients treated at Sina Hospital in Tehran over the past decade. We highlighted and discussed critical issues such as the importance of molecular profiling in predicting OS, the association of glioma survival with prognostically favorable clinical factors, and future research priorities for this patient population.

93

94 Materials and methods

95 Population characteristics and study design

96

97 This retrospective study involved patients aged 11 years and older hospitalized at Sina Hospital in Tehran, Iran, from March 2012 to September 2020. The Ethics and Research 98 Committee of Tehran University of Medical Science, Neurosurgical Department of Sina 99 Hospital (IR.TUMS.SINAHOSPITAL.REC.1399.111) approved this project. Included 100 101 patients had a confirmed diagnosis of glioma based on histological examination. Various data points were collected, including age, gender, extent of tumor resection, tumor location, 102 chemo/radiotherapy details, and genomic profiling information such as IDH1 status, MGMT 103 104 methylation, telomerase reverse transcriptase (TERT) promoter mutation, and epidermal growth factor receptor (EGFR) amplification. Data were obtained by examining patient 105 106 hospital records and the use of a data collection form. The classification of all tumors was 107 performed according to the WHO classification system. The male-to-female ratio and average age at diagnosis were calculated for each histological subtype. To maintain ethical standards, 108 109 patient information was extracted from archived records using pseudonyms to ensure the 110 confidentiality of participants. This study does not include any patient-specific information. Patients who underwent emergency operations and those with a Karnofsky Performance 111 112 Status (KPS) score below 70 and/or a history of psychiatric diseases were excluded (please 113 see Figure 1 for further details).



115

116 Figure 1 Study design and flow chart of patient selection (Created with BioRender.com).

117

118 Genetic profile

119 A Qiagen ffpe (formalin-fixed paraffin-embedded) kit was used for sample extraction, Master

- ABI for PCR, and Qiagen q24 qangen Stanford University for pyrosequencing.
- 121

122 Statistical analysis

123 The primary focus of our study was to assess the impact of specific clinical variables and molecular profiles on overall survival (OS), defined as the duration from the day of tumor 124 125 diagnosis to the date of death from any cause. To gain insights into the characteristics of the 126 patients, we conducted a thorough descriptive analysis. Descriptive statistics were employed to summarize continuous measures, including the number of observed values, median, 127 standard deviation, median, and range. To examine the differences between subgroups, 128 categorized data were compared using the Chi-square (χ^2) test. Furthermore, we employed the 129 two-tailed Student's t-test to analyze the age distribution comparison. The reverse Kaplan-130 131 Meier method was utilized to estimate the median survival time. Survival curves were generated using Kaplan-Meier estimates, and differences between the curves were analyzed 132 using the log-rank test. A two-tailed p-value < 0.05 was considered statistically significant. 133 We used Cox proportional hazards regression analysis to evaluate the impact of measured 134 variables on patient survival in multivariate adjusted models, using a stepwise Wald backward 135 136 selection procedure. All statistical analyses were performed using R software version 4.1.0.

137

138 **Results**

139 A complete flow diagram of patient selection is provided in **Figure 1**. This study investigated the association between OS and various factors, including gender, age, distinct tumor grades, 140 141 the extent of resection, multiple surgeries, radio- and chemotherapy received, mutational 142 profiles in IDH1 and TERT, EGFR alterations, and methylation of the MGMT promoter. Among the cohort of 186 patients meeting the inclusion criteria, a combined treatment 143 approach incorporating both radiation therapy and chemotherapy was administered to 58 144 patients. Additionally, 11 patients received radiation therapy as a standalone treatment, while 145 5 patients exclusively underwent chemotherapy. 146

147

148 Association between glioma grades and parameters studied

Figure 2 provides an overview of the prevalence of genetic and epigenetic alterations 149 identified in the 186 glioma patients with available follow-up. A detailed description of the 150 clinical characteristics and molecular profiling observed in the patients can be found in Table 151 152 **1.** Patients were grouped based on the degree of glioma. The median age of patients with grade II, III, and IV tumors was 40.0, 44.5, and 45.5 years, respectively. This patient cohort 153 with newly diagnosed glioma was comprised of 121 (65.1%) males and 65 (34.9%) females, 154 as shown in **Figure 3**. The χ^2 value was estimated to compare the expected ratios with the 155 observed ratios separately for sex groups, age groups, tumor grade, radiotherapy, and 156 chemotherapy across different tumor grades. Both men and women demonstrated an increase 157 in mortality with an increasing degree of glioma (grade IV) (Figure 4A). An analysis of 158 patient age and mortality rates revealed that in both age groups (age < 50 and age ≥ 50) the 159 mortality rate significantly higher in patients with grade IV glioma compared to the other 160 groups (Figure 4B). Mortality rate of patients with grade IV tumors in both the unilobar and 161 162 multilobar groups was significantly higher than in patients with grade II and III glioma (Figure 4C). Only patients with grade IV tumors that underwent chemotherapy showed 163 164 significantly lower mortality rates and higher survival than patients who did not (Figure 4D). 165 Similarly, patients with grade IV tumors subjected to radiotherapy showed a higher survival rate compared to those not treated (Figure 4E); both chemo- and radiotherapy appeared to 166 improve survival in grade III patients as well, although these effects did not reach statistical 167 significance (Figures 4D, E). 168

169

170

171



- 173 Figure 2 The distribution of molecular and clinical characteristics among the included glioma patient
- 174 population. Molecular classification was arranged by the three histological types of gliomas (grades II,
- 175 III, and IV)

- 10.

-	0	2
Characteristics	Cases	%
Age group		
< 20 years	8	4.3
20-50 years	109	58.6
> 50 years	69	37.1
Median age (range): years	44.5 (11 -	- 81)
Gender		01)
Male	121	65.1
Female	65	34.9
Distinct tumor grades	05	54.7
Grade II	40	21.5
Grade III	40	21.5
Grade IV	102	54.8
Extent of respection (EOP)	102	54.0
Gross total respection (GTP)	156	82.0
Near total resection (NTP)	20	16.1
Turner leastion by labe	50	10.1
	0 <i>5</i>	45 7
Multilobar	85	45.7
Temporal	16	8.6
Frontal	38	20.4
Occipital	11	5.9
Parietal	17	9.1
Insular or cerebellum	6	3.2
Unknown	13	7.0
Survival		
Dead	128	68.8
Alive	58	31.2
Survival ≤ 12	20	15.6
$12 < Survival \le 24$	60	46.9
$24 < Survival \le 36$	18	14.1
Survival ≥ 36	30	23.4
Multiple surgeries		
Yes	62	33.3
No	124	66.7
Anesthesia		
Awake	22	12.6
General	152	87.4
Chemotherapy		
Yes	63	33.9
No	123	66.1
Adjuvant radiotherapy		
Yes	69	37.1
No	117	62.9
Radio/chemo therapy		
Yes	58	31.2
No	128	68.8
Type 2 diabetes mellitus		
Yes	14	7.5
No	172	92.5

Table 1 Characteristics of the 186 patients with glioma in this study



195 Figure 3 Pie charts showing the frequency of specific characteristics among the 186 patients of the 196 studied glioma cohort. The area of each segment is proportional to the number of patients

197

198



Figure 4 The ratios of different grades of glioma in the examined groups are shown in (A) gender *vs.* survival, (B) age groups *vs.* survival, (C) glioma *vs.* survival, (D) chemotherapy *vs.* survival, and (E)

adjuvant radiotherapy vs. survival. The Chi-square test was used to compare the groups

203

204

206 IDH1 and EGFR mutation allele frequencies

207 In this study, the IDH1 and EGFR status was evaluated in tissue samples from each patient (Figure 2), and the frequencies of IDH1 and EGFR mutations were determined 208 209 (Tables 2). It should be noted that genetic profile information was available for 132 out of the 210 total 186 patients included in the study. Among the grade II gliomas (n=28), 19 cases (67.8%)exhibited IDH1 mutations, while 3 patients (10.7%) had EGFR mutations. In grade III 211 212 gliomas (n=26), 22 cases (84.6%) showed IDH1 mutations, and no EGFR mutations were observed. In grade IV gliomas (n=78), 64 patients (82.0%) had IDH1 mutations, and 1 patient 213 214 (1.2%) had an EGFR mutation. Among the 26 grade III glioma samples, 4 cases (15.3%) had 215 wild-type IDH1, and 26 cases (100%) had wild-type EGFR. On the other hand, in the 78 216 grade IV glioma cases, 14 cases (17.9%) had wild-type IDH1, and 77 cases (98.7%) had wild-217 type EGFR. It is worth noting that the frequency of IDH1 mutations was higher compared to EGFR mutations in grade II, III, and IV gliomas. Specifically, we observed only 3, 0, and 1 218 219 mutation(s) in the EGFR gene among grade II, III, and IV gliomas, respectively.

220

Table 2 The distribution of IDH1, MGMT, TERT, and EGFR mutations among different histological
 grades of glioma in 132 patients with available genetic profiling

Molecular assay	Different grades	Different grades of glioma tumor			
	Grade II (28)	Grade III (26)	Grade IV (78)		
IDH1 status					
Wild type	9	4	14	27	
Mutant	19	22	64	105	
MGMT methylation status					
Methylated	21	17	56	94	
Non-methylated	7	9	22	38	
TERT promoter status					
Wild type	23	26	63	112	
Mutant	5	0	15	20	
EGFR amplification status					
Wild type	25	26	77	128	
Mutant	3	0	1	4	

223

224 Allele frequencies of TERT and MGMT genes and clinical response in patients

225 In the study cohort of 132 cases, the IDH1, MGMT, TERT, and EGFR status were evaluated 226 successfully. Among these cases, 105 (79.5%) exhibited IDH1 mutations, 20 (15.1%) had 227 TERT mutations, 94 (71.2%) were classified as MGMT-methylated tumors, and four (3%) 228 showed EGFR mutations. MGMT methylation rates were lower (6 patients) in patients with IDH1 wild-type tumors and higher (88 patients) in patients with IDH1 mutant tumors. Of the 229 230 186 patients with treatment recorded, 63 (33.9%) and 69 (37.1%) received TMZ and 231 radiotherapy, respectively. As of the time of final data collection, 58 patients (31.2%) were 232 still alive or lost to follow-up.

In this study of 173 patients, tumors in the frontal lobe were the most prevalent (95 patients), followed by tumors in the temporal lobe (76 patients), parietal lobe (68 patients), occipital lobe (29 patients), and insular cortex or cerebellum (19 patients). The most common

tumor combinations were observed in the frontal + temporal (18 patients), parietal + frontal 236 237 (15 patients) and parietal + frontal + temporal (15 patients) lobes (Figure 5A). None of the 238 patients had tumors in all four brain lobes simultaneously. Occipital lobe tumors tended to manifest as isolated cases in glioma patients, with 11 out of 29 cases showing no signs of 239 240 tumors in other brain lobes (Figure 3 and 5A). Anatomically, the location of tumors was 241 primarily multilobar (85 of 173 patients), with a subset of patients demonstrating frontal (21.9%, n = 38) and temporal (9.2%, n = 16) gliomas. Other tumor locations included the 242 parietal lobe (9.8%, n = 17), insular cortex or cerebellum (3.5%, n = 6), and occipital lobe 243 (6.4%, n = 11) (Figure 5A). The tumor location was unknown in 13 patients due to 244 245 unavailable clinical follow-up and imaging data.

The alluvial plot (**Figure 6**) shows the distribution and relationships between survival rate, tumor grade, TERT genetic profile, and adjuvant radiotherapy. A considerable number of patients with tumor grade IV (n = 102) had a high mortality rate (90%). Furthermore, the chart illustrates that patients who received adjuvant radiotherapy had a significantly lower mortality rate. The association between the TERT genetic profile and survival rate further underscores the relevance of genetic characteristics in prognostic evaluations.





Figure 5 (A) Venn diagram illustrating the distribution of 173 patients with tumors in the "Temporal"," Frontal"," Occipital"," Parietal" and "Insular or cerebellum" lobes of the brain. (B) The lobes of brain (Created with BioRender.com).

- 256
- 257
- 258
- 259



Figure 6 The alluvial plot showing the distribution of patients, survival subgroup, and histological
 grade in relation to (A) TERT alleles and (B) adjuvant radiotherapy

263

260

264 Survival analysis

Results of multivariate Cox regression analyses for clinical characteristics and molecular profiles, including IDH1, TERT, and MGMT, are presented in **Table 3**. In multivariate models, the histological grade of the tumor (HR, 5.70; 95% CI, 3.54-9.18; P < 0.0001), adjuvant radiotherapy (HR, 0.41; 95% CI, 0.19-0.83; P < 0.014), IDH status (HR for IDH1 mutant status, 2.05; 95% CI, 1.07-4.32; P < 0.026), TERT status (HR for unmethylated status, 2.15; 95% CI, 1.08-3.88; P < 0.030) were significantly associated with OS (**Table 3**).

271

272 Table 3 Prognostic univariate and multivariate Cox regression analyses in glioma patients

Characteristic	Patients	Univariate	Multivariate			
	number	<i>p</i> -value	<i>p</i> -value	HR	95% CI for HR	
					Lower	Upper
Age, per year (<50 vs >50)	128	0.022*	0.0534	1.0128	0.9998	1.026
Gender (Male vs Female)	128	0.26	0.4336	1.1675	0.7923	1.7204
Histological grade (grades II, III, and IV)	128	$2.9\times10^{13}\text{m}$	7.67×10^{-13} *	5.7041	3.5431	9.1829
Extent of resection (GTR vs NTR)	128	0.55	0.6865	1.1092	0.6705	1.835
Glioma (unilobar vs multilobar)	128	0.84	0.7637	0.9381	0.6185	1.4228
Chemotherapy (Yes vs No)	128	0.76	0.2542	1.4972	0.7481	2.9963
Adjuvant radiotherapy (Yes vs No)	128	0.0047*	0.0142*	0.4017	0.1938	0.8326
IDH1 status (WT vs Mutant)	91	0.83	0.0262*	2.0562	1.0749	4.317
TERT mutation (WT vs Mutant)	91	$2.6 imes 10^{-5} st$	0.0305*	2.1542	1.0891	3.882
MGMT methylation (WT vs Mutant)	91	0.49	0.4238	0.7986	0.4604	1.385

273 * P< 0.05.

275 Factors associated with overall survival

276 The median survival of patients was 20 months (600 days; Figure 7A), with 15.6% and 277 46.9% of patients alive at 12 and 24 months, respectively. Nineteen patients (14.8%) survived 278 for longer than 48 months (4 years) and were considered long-term survivors. Interestingly, 279 the four patients who were still alive when the dataset was finalized (OS > 50, 53, 65, and 71280 months) exhibited mutated IDH1 and methylated MGMT. Initially, we assessed whether any 281 genetic alterations were associated with survival through univariate and multivariate analyses 282 (**Table 3**). A more stringent multivariate analysis, which only incorporates parameters with P 283 > 0.05 in the univariate analyses, revealed the same parameters were independent prognostic 284 factors. Glioma patients with IDH1 mutations had a median OS of 21 months compared to 285 17.5 months for those without an IDH1 mutation (Figure 7G). Methylation of MGMT was 286 associated with a median OS of 20.5 months compared to 19 months in non-methylated cases 287 (Figure 7I). Patients with a TERT promoter mutation exhibited a median OS of 16 months, whereas patients with a non-mutated TERT promoter had a median OS of 21 months (Figure 288 289 **7H**). Notably, patients with solely an IDH1 mutation exhibited the most favorable survival, with a median survival of 21 months. Subsequently, patients with both an IDH1 mutation and 290 291 MGMT methylation experienced a slightly lower median survival of 20 months. In contrast, 292 patients lacking either an IDH1 mutation or MGMT methylation had the shortest median 293 survival of 16 months. It is worth noting that the molecular profile analysis, specifically regarding wild-type IDH1 and MGMT methylation, encompassed a limited sample size of 294 295 only three patients who exhibited survival durations of 18, 50, and 62 months, respectively. 296 Furthermore, we conducted an assessment of the prognostic significance of histological grade 297 and clinical characteristics. Among the histological subgroups, Grades II and III demonstrated a more favorable prognosis, with median OS durations of 51 and 46 months, respectively. 298 299 Conversely, Grade IV was associated with an extremely poor outcome, with an OS of 18 300 months (Figure 7B). Additionally, patients under the age of 50 displayed a more favorable prognosis, with a median OS of 23 months, compared to the subgroup aged 50 years and 301 302 above, which exhibited a median OS of 19 months (Figure 7D).

303



Figure 7 The distribution of glioma patient survival and Kaplan-Meier curves for overall survival are
shown for 8 risk groups. (A) The box plot illustrates the overall survival (months) of glioma patients.
Kaplan-Meier curves show survival probabilities in relation to (B) the histological grade, (C) age
groups, (D) uni- and multilobar glioma, (E) gender, (F) extent of resection, (G) IDH1 status, (H)
TERT status, and (I) MGMT status.

316 Discussion

317 Our results showed a difference of 40, 44.5, and 45.5 years in the median age of patients with 318 grade II, III, and IV tumors, respectively. Gliomas were more common in males than in 319 females, and the death rate increased with glioma grade, with the highest mortality in grade 320 IV patients. GBM is the most prevalent malignant brain tumor in adults, accounting for 54% 321 of all cases. The incidence of GBM increases with age, and the development of illnesses, 322 especially those affecting the CNS, is more likely among older people. Wild-type IDH GBM 323 is the most common aggressive primary brain tumor in adults, with an average diagnostic age 324 of 68-70 years, and progresses rapidly. Elderly (65 and older) GBM patients may have a 325 worse post-treatment survival rate due to age-related changes, such as diminished immune system function and persistent neuroinflammation^{10, 11}. A negative correlation exists between 326 the age at which GBM is identified and prognosis. The 10-year relative survival rate declines 327 from 15.2% to 5.7% between 20-44 and 45-54 years of age, respectively $^{12, 13}$. 328

The results of the current study show that glioma patients with IDH1 mutations (IDH1mt) 329 330 had a median OS of 21 months versus 17.5 months for those without an IDH1 mutation. In 331 addition, methylation of the MGMT (MGMTmet) was associated with a median OS of 20.5 332 months versus 19 months in patients with a non-methylated. The combination of IDH1 333 mutations and MGMT methylation status is a more accurate predictor of survival in 334 glioblastoma compared to either IDH1 or MGMT alone. Glioblastoma patients were categorized into 3 distinct genotypes based on the genetic and epigenetic characteristics of 335 IDH1 and MGMT: GBM patients with IDH1mt/MGMTmet had the longest survival, 336 337 followed by patients with IDH1mt/MGMTunmet or IDH1wt/MGMTmet, and patients with IDH1wt/MGMTunmet had the shortest survival¹⁴. Improved prognosis has been linked to 338 tumor molecular characteristics such as MGMT promoter methylation and IDH1 mutation¹⁵⁻ 339 ¹⁷. Thus, MGMT methylation positively impacts survival and responsiveness to TMZ therapy 340 ¹⁵. In addition, IDH and MGMT co-methylation is linked to a better prognosis and predicts 341 the response to chemotherapy and surgical resection 16 . 342

343 Surgical resection, radiation, and TMZ chemotherapy constitute the standard treatment for GBM. Despite the intensive nature of this therapy, the tumor reoccurs within 7 to 10 months 344 following surgery in 75-90% of GBM patients ¹⁸⁻²⁰. A study utilizing molecular testing 345 revealed distinct genetic profiles among GBM survivors. Notably, mutations in the IDH genes 346 (IDH1 and IDH2) and methylation of the MGMT promoter were identified as two significant 347 factors associated with a more favorable response to standard clinical care ²¹. Patients with 348 mutant IDH1/2 GBM exhibited superior outcomes to those with wild-type IDH tumors, with a 349 survival of 14 and 42 months, respectively ²². Literature suggests a strong correlation between 350 TERT gene polymorphisms and an increased risk of glioma in patients²³. TERT mutations 351 are also linked to biomarkers such as IDH1, 1p19q, TP53, and EGFR²⁴. 352

Gliomas are more prevalent in men than in women. The tumors of glioblastoma patients showed huge genetic sex differences linked to survival. According to a study on differentially expressed genes in the tumor clusters, survival in men was impacted the most by genes that govern cell division. Regarding survival in females, integrin gene expression was the most critical mechanism for tumor dissemination [23]. Other work indicated that male patients had

the lowest cancer-specific survival (CSS) rates throughout localized cancer stages and various
 age groupings, which was confirmed by stratified analysis ^{25, 26}.

One study reported that women with IDH1-mutant tumors were concentrated in the group 360 361 with the most favorable prognosis, while in males; the mutations were spread out across all 362 groups. Considering IDH1 mutations have been linked to higher survival in glioblastoma patients, the longest-surviving female cluster is consistent with this theory. However, this was 363 not the case for men²⁵. Our present study indicates that patients with a mutation in TERT had 364 a median OS of 16 months compared to 21 months in those without a TERT mutation. In 365 addition, MGMT methylation status was shown to affect the prognostic value of a TERT 366 promoter mutation. Only TERT-mutated GBM with MGMT methylation may respond to 367 TMZ; therefore, TMZ may not benefit all patients with MGMT-methylated GBM²⁷. Long-368 term follow-up of patients with TERT promoter mutant GBMs showed a high correlation 369 370 between the prognosis and the presence of multifocal/distant lesions. There was a associated 371 between EGFR amp/gain, CDKN2A deletion, and PTEN loss, as well as a negative correlation between CDK4 and TP53 deletion for the TERTp mutation²⁸. EGFR mutations 372 373 have been demonstrated to be effective prognostic indicators of OS in IDH-wildtype GBM 374 patients. Moreover, there is data to suggest that EGFR amplification is evident in high-grade gliomas (25%). EGFR amplification was also observed to be limited to IDH wild-type (26%) 375 376 and TERT mutant (27%) gliomas, occurring irrespective of MGMT promoter methylation status and being mutually exclusive with 1p/19q co-deletion (LOH)²⁹. The functional 377 connection between EGFR and p53 in GBM is intriguing. Thus, EGFR has been shown to 378 379 reduce the activity of wild-type p53 by increasing the interaction between DNA-PKcs and p53. Either EGFR or DNA-PKc knockdown enhanced the transcriptional activity of wild-type 380 381 p53 due to a reduced interaction between p53 and DNA-PKcs. These results revealed a unique 382 non-canonical regulatory axis between EGFR and wild-type p53 in GBM, with unexpected biological functions ³⁰. 383

384 We observed an apparent difference (although not statistically significant) in the OS of gross (GTR) versus near total resection (NTR) glioma patients, which is consistent with 385 findings by Abdelfath et al.³¹. GTR appears to be more beneficial than subtotal resection 386 (STR) in extending the life of elderly individuals with high-grade glioma³². Aggressive 387 388 surgical resection should be considered for older GBM patients, especially those with relatively low KPS. Intraoperative magnetic resonance imaging (ioMRI) does not seem to 389 390 provide any significant advantage over intraoperative ultrasonography (ioUS) in experienced hands in this population. Still, it may significantly prolong the duration of surgery, which is a 391 modifiable prognostic factor that affects care ³³. Other work showed a correlation between 392 maximal tumor excision and OS in all categories of glioblastoma patients. Additionally, 393 maximal resection of non-contrast-enhanced (NCE) tumors was associated with longer OS in 394 395 younger patients, independent of IDH status, and in patients with IDH-wild-type glioblastoma, regardless of the methylation status of the promoter region of the DNA repair 396 enzyme O⁶-methylguanine-DNA methyltransferase ³⁴. 397

Within our cohort, the anatomical tumor location was generally confined to a multi-lobe, primarily multilobar disease (45.6%), with some patients demonstrating tumor growth in the frontal (20.4%) and temporal (8.6%) lobes. Other tumor locations included the parietal lobe

401 (9.1%), insular cortex or cerebellum (3.2%), and occipital lobe (5.9%). Most glioblastomas 402 develop in the periventricular white matter areas close to the subventricular zone. MGMT 403 promoter methylation tumors are more prevalent in the left temporal lobe, particularly in 404 patients with GBM, an IDH1 mutant tumor, tumors with the proneural gene expression 405 subtype, or frontal lobe tumors missing PTEN deletion. IDH1 mutation-associated MGMT-406 methylated tumors tended to manifest in the left frontal lobe, whereas EGFR-amplified and 407 EGFR variant 3-expressing tumors occurred most frequently in the left temporal lobe. A 408 comparable area in the left temporal lobe was associated with excellent radiochemotherapy response and improved survival³⁵. In another study, tumors in the right occipitotemporal 409 periventricular white matter were substantially related to poor survival in both training and 410 test cohorts and had a greater tumor volume than tumors in other regions. Right parietal 411 tumors were associated with hypoxia pathway enrichment and platelet-derived growth factor 412 receptor (PDGFRA) amplification, deeming these processes appropriate subgroup-specific 413 414 treatment targets. Additionally, central tumor placement was associated with a worse 415 prognosis. In elderly individuals, the distance from the center of the third ventricle to the contrast-enhancing tumor border may be a practical prognostic indicator ³⁵⁻³⁷. 416

Our study recognizes certain limitations, including the utilization of data from a single 417 418 center and an underpowered analysis for detecting differences among patient subgroups. The scarcity of data on comorbidities such as lung infections, renal disorders, seizures, high blood 419 420 pressure, and paresthesia emphasizes the necessity for more extensive and standardized data 421 collection. Moreover, we did not adjust for multiple comparisons. However, the study's 422 strength lies in its meticulous examination of factors associated with glioma prognosis and 423 treatment response, presenting valuable insights for clinical decision-making. Additionally, 424 we highlighted the synergistic impact of specific genetic profiles and radiotherapy, identifying 425 potential targets for personalized treatment strategies. Despite the acknowledged limitations, 426 this study offers a comprehensive analysis of crucial factors influencing glioma prognosis and 427 treatment response.

428

429 Conclusion

430 The present study aimed to investigate the impact of clinical and molecular factors on the overall survival of glioblastoma patients. Multivariate Cox regression analysis revealed that 431 432 histological tumor grade, adjuvant radiotherapy, IDH status, and TERT promoter status were 433 significantly associated with overall survival. Notably, patients with IDH1 mutations and 434 TERT promoter mutations exhibited longer survival. Factors such as extensive tumor 435 removal, smaller tumor size, and prompt initiation of radiation therapy after surgery were 436 associated with favorable prognoses. Patients with higher tumor grades had poorer outcomes, 437 while those who received adjuvant radiotherapy showed improved survival. In conclusion, 438 this study highlights the importance of molecular and clinical characteristics in predicting 439 overall survival in glioblastoma patients and provides valuable insights for personalized 440 treatment strategies.

442 Funding

The Asu Vanda Gene Industrial Research Company, Tehran (1533666398), Iran, provided
funding support for this study.

445 **Ethic**

446 The Ethics and Research Committee of Tehran University of Medical Science, Neurosurgical

447 Department of Sina Hospital (IR.TUMS.SINAHOSPITAL.REC.1399.111) approved this

448 study.

449 Acknowledgement

450 We appreciate Sina Hospital for providing the required testing facilities and equipment for the 451 study.

452 Author contribution

453 Amir Barzegar Behrooz: drafting & editing of the manuscript with input from all authors.

454 Hadi Darzi Ramandi: contributed to data analysis and interpretation, and drafting & editing

455 of the manuscript. Hamid Latifi-Navid: reviewing & editing of the manuscript. Payam

456 Peymani: reviewing & editing of the manuscript. Rahil Tarharoudi, Nasrin Momeni and

457 Mohammad Mehdi Sabaghpour Azarian: assisted in data curation. Sherif Eltonsy:

- 458 Reviewing & editing of the manuscript. Ahmad Pour-Rashidi: supervised the project and
- 459 contributed to the writing, reviewing, and editing. Saeid Ghavami: supervision of the project,
- 460 resources, and final draft. All authors approved the final document as submitted.

461 **Competing interests**

462 The authors affirm that no conflicts of interest exist.

463 Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

467

468 **References:**

- (1) Dunn, G. P.; Rinne, M. L.; Wykosky, J.; Genovese, G.; Quayle, S. N.; Dunn, I. F.; Agarwalla, P.
- K.; Chheda, M. G.; Campos, B.; Wang, A.; et al. Emerging insights into the molecular and cellular
 basis of glioblastoma. *Genes Dev* 2012, 26 (8), 756-784. DOI: 10.1101/gad.187922.112 From NLM.
- basis of glioblastoma. *Genes Dev* 2012, 26 (8), 756-784. DOI: 10.1101/gad.187922.112 From NLM.
 (2) Nahid Dadashzadeh Asl1a, T. S. a., Meisam Haghmoradi 3, Ahmad Pour-Rashidi 4, ; Mohammad
- 472 (2) Nand Dadasizaden Astra, 1. S. a., Meisan Haginnoradi S, Anniad Four-Kashdi 4, , Mohanniad 473 Mehdi Sabaghpour Azarian 5, H. H., *, Vahid Hosseinpour 7, Amir ; Barzegar Behrooz 8. Prevalence
- 474 of Central Nervous System Tumors in Iran: A Systematic and Meta-analysis. *Latin American Journal*
- 475 of Pharmacy **2023**, 42 (10), 8-17.
- (3) Minniti, G.; Lombardi, G.; Paolini, S. Glioblastoma in Elderly Patients: Current Management and
 Future Perspectives. *Cancers (Basel)* 2019, *11* (3). DOI: 10.3390/cancers11030336 From NLM.
- 478 (4) Weller, M.; Wick, W.; Aldape, K.; Brada, M.; Berger, M.; Pfister, S. M.; Nishikawa, R.;
- 479 Rosenthal, M.; Wen, P. Y.; Stupp, R.; et al. Glioma. *Nature Reviews Disease Primers* 2015, 1 (1),
 480 15017. DOI: 10.1038/nrdp.2015.17.
- 481 (5) Zhang, Y. H.; Li, Z.; Zeng, T.; Pan, X.; Chen, L.; Liu, D.; Li, H.; Huang, T.; Cai, Y. D.
- 482 Distinguishing Glioblastoma Subtypes by Methylation Signatures. Front Genet 2020, 11, 604336.
- 483 DOI: 10.3389/fgene.2020.604336 From NLM.
- (6) Dubrow, R.; Darefsky, A. S. Demographic variation in incidence of adult glioma by subtype,
 United States, 1992-2007. *BMC Cancer* 2011, *11*, 325. DOI: 10.1186/1471-2407-11-325 From NLM.
- 486 (7) van den Bent, M. J.; Geurts, M.; French, P. J.; Smits, M.; Capper, D.; Bromberg, J. E. C.; Chang,
- 487 S. M. Primary brain tumours in adults. *Lancet* **2023**, *402* (10412), 1564-1579. DOI: 10.1016/s0140-6736(23)01054-1 From NLM.
- (8) Mohammed, S.; Dinesan, M.; Ajayakumar, T. Survival and quality of life analysis in glioblastoma
 multiforme with adjuvant chemoradiotherapy: a retrospective study. *Rep Pract Oncol Radiother* 2022,
 27 (6), 1026-1036. DOI: 10.5603/RPOR.a2022.0113 From NLM.
- 492 (9) Baid, U.; Rane, S. U.; Talbar, S.; Gupta, S.; Thakur, M. H.; Moiyadi, A.; Mahajan, A. Overall
- 492 (9) Baid, O., Raid, S. O., Faldar, S., Gupta, S., Hakur, M. H., Moryadi, A., Manajan, A. Overan
 493 Survival Prediction in Glioblastoma With Radiomic Features Using Machine Learning. *Front Comput* 494 *Neurosci* 2020, *14*, 61. DOI: 10.3389/fncom.2020.00061 From NLM.
- 495 (10) Miller, K. D.; Ostrom, Q. T.; Kruchko, C.; Patil, N.; Tihan, T.; Cioffi, G.; Fuchs, H. E.; Waite, K.
 496 A.; Jemal, A.; Siegel, R. L.; et al. Brain and other central nervous system tumor statistics, 2021. *CA*
- 497 *Cancer J Clin* **2021**, *71* (5), 381-406. DOI: 10.3322/caac.21693 From NLM.
- 498 (11) Kim, M.; Ladomersky, E.; Mozny, A.; Kocherginsky, M.; O'Shea, K.; Reinstein, Z. Z.; Zhai, L.;
 499 Bell, A.; Lauing, K. L.; Bollu, L.; et al. Glioblastoma as an age-related neurological disorder in adults.
- 50 Neurooncol Adv 2021, 3 (1), vdab125. DOI: 10.1093/noajnl/vdab125 From NLM.
- (12) Rabab'h, O.; Al-Ramadan, A.; Shah, J.; Lopez-Negrete, H.; Gharaibeh, A. Twenty Years After
 Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival. *Cureus* 2021, *13* (6), e16061.
 DOI: 10.7759/cureus.16061 From NLM.
- 504 (13) Ostrom, Q. T.; Gittleman, H.; Truitt, G.; Boscia, A.; Kruchko, C.; Barnholtz-Sloan, J. S.
- 505 CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in
- the United States in 2011-2015. *Neuro Oncol* 2018, 20 (suppl_4), iv1-iv86. DOI:
 10.1093/neuonc/noy131 From NLM.
- 508 (14) Molenaar, R. J.; Verbaan, D.; Lamba, S.; Zanon, C.; Jeuken, J. W. M.; Boots-Sprenger, S. H. E.;
- 509 Wesseling, P.; Hulsebos, T. J. M.; Troost, D.; van Tilborg, A. A.; et al. The combination of IDH1
- 510 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or
- 511 MGMT alone. *Neuro-Oncology* **2014**, *16* (9), 1263-1273. DOI: 10.1093/neuonc/nou005 (accessed 512 3/4/2024).
- 513 (15) Louis, D. N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.
- 514 K.; Ohgaki, H.; Wiestler, O. D.; Kleihues, P.; Ellison, D. W. The 2016 World Health Organization
- 515 Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016, 131 (6),
- 516 803-820. DOI: 10.1007/s00401-016-1545-1 From NLM.
- 517 (16) Molenaar, R. J.; Verbaan, D.; Lamba, S.; Zanon, C.; Jeuken, J. W.; Boots-Sprenger, S. H.;
- 518 Wesseling, P.; Hulsebos, T. J.; Troost, D.; van Tilborg, A. A.; et al. The combination of IDH1

- 519 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or 520 MGMT alone. Neuro Oncol 2014, 16 (9), 1263-1273. DOI: 10.1093/neuonc/nou005 From NLM.
- 521 (17) Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.;
- 522 Hainfellner, J. A.; Mason, W.; Mariani, L.; et al. MGMT gene silencing and benefit from 523 temozolomide in glioblastoma. N Engl J Med 2005, 352 (10), 997-1003. DOI:
- 524 10.1056/NEJMoa043331 From NLM.
- 525 (18) Ho, V. K.; Reijneveld, J. C.; Enting, R. H.; Bienfait, H. P.; Robe, P.; Baumert, B. G.; Visser, O.
- 526 Changing incidence and improved survival of gliomas. Eur J Cancer 2014, 50 (13), 2309-2318. DOI: 527
- 10.1016/j.ejca.2014.05.019 From NLM.
- 528 (19) Aldape, K.; Zadeh, G.; Mansouri, S.; Reifenberger, G.; von Deimling, A. Glioblastoma: 529 pathology, molecular mechanisms and markers. Acta Neuropathol 2015, 129 (6), 829-848. DOI: 530 10.1007/s00401-015-1432-1 From NLM.
- 531 (20) Omuro, A.; DeAngelis, L. M. Glioblastoma and other malignant gliomas: a clinical review. Jama 532 2013, 310 (17), 1842-1850. DOI: 10.1001/jama.2013.280319 From NLM.
- 533 (21) Jovčevska, I. Genetic secrets of long-term glioblastoma survivors. Bosn J Basic Med Sci 2019, 19 534 (2), 116-124. DOI: 10.17305/bjbms.2018.3717 From NLM.
- 535 (22) Molinaro, A. M.; Taylor, J. W.; Wiencke, J. K.; Wrensch, M. R. Genetic and molecular 536 epidemiology of adult diffuse glioma. Nat Rev Neurol 2019, 15 (7), 405-417. DOI: 10.1038/s41582-
- 537 019-0220-2 From NLM.
- 538 (23) Yuan, Y.; Qi, C.; Maling, G.; Xiang, W.; Yanhui, L.; Ruofei, L.; Yunhe, M.; Jiewen, L.; Qing, M.
- 539 TERT mutation in glioma: Frequency, prognosis and risk. J Clin Neurosci 2016, 26, 57-62. DOI: 540 10.1016/j.jocn.2015.05.066 From NLM.
- 541
- (24) Powter, B.; Jeffreys, S. A.; Sareen, H.; Cooper, A.; Brungs, D.; Po, J.; Roberts, T.; Koh, E. S.; 542
- Scott, K. F.; Sajinovic, M.; et al. Human TERT promoter mutations as a prognostic biomarker in 543 glioma. J Cancer Res Clin Oncol 2021, 147 (4), 1007-1017. DOI: 10.1007/s00432-021-03536-3 From 544 NLM.
- 545 (25) Yang, W.; Warrington, N. M.; Taylor, S. J.; Whitmire, P.; Carrasco, E.; Singleton, K. W.; Wu, 546 N.; Lathia, J. D.; Berens, M. E.; Kim, A. H.; et al. Sex differences in GBM revealed by analysis of 547 patient imaging, transcriptome, and survival data. Sci Transl Med 2019, 11 (473). DOI: 548 10.1126/scitranslmed.aao5253 From NLM.
- 549 (26) Tian, M.; Ma, W.; Chen, Y.; Yu, Y.; Zhu, D.; Shi, J.; Zhang, Y. Impact of gender on the survival 550 of patients with glioblastoma. Biosci Rep 2018, 38 (6). DOI: 10.1042/bsr20180752 From NLM.
- 551 (27) Vuong, H. G.; Nguyen, T. Q.; Ngo, T. N. M.; Nguyen, H. C.; Fung, K. M.; Dunn, I. F. The
- 552 interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of 553 glioma patients: a meta-analysis. BMC Cancer 2020, 20 (1), 897. DOI: 10.1186/s12885-020-07364-5
- 554 From NLM.
- 555 (28) Kikuchi, Z.; Shibahara, I.; Yamaki, T.; Yoshioka, E.; Shofuda, T.; Ohe, R.; Matsuda, K. I.; Saito,
- 556 R.; Kanamori, M.; Kanemura, Y.; et al. TERT promoter mutation associated with multifocal 557 phenotype and poor prognosis in patients with IDH wild-type glioblastoma. *Neurooncol Adv* 2020, 2
- 558 (1), vdaa114. DOI: 10.1093/noajnl/vdaa114 From NLM.
- 559 (29) Hölzl, D.; Hutarew, G.; Zellinger, B.; Alinger-Scharinger, B.; Schlicker, H. U.; Schwartz, C.;
- 560 Sotlar, K.; Kraus, T. F. J. EGFR Amplification Is a Phenomenon of IDH Wildtype and TERT Mutated
- 561 High-Grade Glioma: An Integrated Analysis Using Fluorescence In Situ Hybridization and DNA 562 Methylome Profiling. Biomedicines 2022, 10 (4). DOI: 10.3390/biomedicines10040794 From NLM.
- 563 (30) Ding, J.; Li, X.; Khan, S.; Zhang, C.; Gao, F.; Sen, S.; Wasylishen, A. R.; Zhao, Y.; Lozano, G.;
- 564 Koul, D.; et al. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a 565 noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro Oncol 2022,
- 566 24 (10), 1712-1725. DOI: 10.1093/neuonc/noac105 From NLM.
- 567 (31) AbdelFatah, M. A. R.; Kotb, A.; Said, M. A.; Abouelmaaty, E. M. H. Impact of extent of 568 resection of newly diagnosed glioblastomas on survival: a meta-analysis. Egyptian Journal of 569 Neurosurgery 2022, 37 (1), 3. DOI: 10.1186/s41984-022-00145-1.
- 570 (32) Han, Q.; Liang, H.; Cheng, P.; Yang, H.; Zhao, P. Gross Total vs. Subtotal Resection on Survival
- 571 Outcomes in Elderly Patients With High-Grade Glioma: A Systematic Review and Meta-Analysis.
- 572 Front Oncol 2020, 10, 151. DOI: 10.3389/fonc.2020.00151 From NLM.

- 573 (33) Barak, T.; Vetsa, S.; Nadar, A.; Jin, L.; Gupte, T. P.; Fomchenko, E. I.; Miyagishima, D. F.;
- Yalcin, K.; Vasandani, S.; Gorelick, E.; et al. Surgical strategies for older patients with glioblastoma. J
 Neurooncol 2021, *155* (3), 255-264. DOI: 10.1007/s11060-021-03862-z From NLM.
- 576 (34) Molinaro, A. M.; Hervey-Jumper, S.; Morshed, R. A.; Young, J.; Han, S. J.; Chunduru, P.; Zhang,
- 577 Y.; Phillips, J. J.; Shai, A.; Lafontaine, M.; et al. Association of Maximal Extent of Resection of
- 578 Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of
- 579 Patients With Newly Diagnosed Glioblastoma. JAMA Oncol 2020, 6 (4), 495-503. DOI:
- 580 10.1001/jamaoncol.2019.6143 From NLM.
- 581 (35) Ellingson, B. M.; Lai, A.; Harris, R. J.; Selfridge, J. M.; Yong, W. H.; Das, K.; Pope, W. B.;
- 582 Nghiemphu, P. L.; Vinters, H. V.; Liau, L. M.; et al. Probabilistic radiographic atlas of glioblastoma
- 583 phenotypes. AJNR Am J Neuroradiol 2013, 34 (3), 533-540. DOI: 10.3174/ajnr.A3253 From NLM.
- 584 (36) Fyllingen, E. H.; Bø, L. E.; Reinertsen, I.; Jakola, A. S.; Sagberg, L. M.; Berntsen, E. M.;
- 585 Salvesen, Ø.; Solheim, O. Survival of glioblastoma in relation to tumor location: a statistical tumor 586 atlas of a population-based cohort. *Acta Neurochir* (*Wien*) **2021**, *163* (7), 1895-1905. DOI:
- 587 10.1007/s00701-021-04802-6 From NLM.
- 588 (37) Liu, T. T.; Achrol, A. S.; Mitchell, L. A.; Du, W. A.; Loya, J. J.; Rodriguez, S. A.; Feroze, A.;
- 589 Westbroek, E. M.; Yeom, K. W.; Stuart, J. M.; et al. Computational Identification of Tumor Anatomic
- 590 Location Associated with Survival in 2 Large Cohorts of Human Primary Glioblastomas. AJNR Am J
- 591 *Neuroradiol* **2016**, *37* (4), 621-628. DOI: 10.3174/ajnr.A4631 From NLM.